Tivdak (Tisotumab Vedotin-tftv)

Tivdak (Tisotumab vedotin-tftv)

Tivdak

Tisotumab vedotin-tftv

Injection: 40mg

Seagen Inc.

Medical Use

Tivdak is a targeted therapy combining a tissue factor-directed antibody with a microtubule inhibitor. It’s used to treat adults with recurrent or metastatic cervical cancer that has progressed despite chemotherapy.

Recommended Dosage: Administer Tivdak at a dose of 2 mg per kg (capped at 200 mg for patients weighing 100 kg or more) via intravenous infusion over 30 minutes every three weeks. Continue treatment until disease progression or unacceptable toxicity occurs. Note that Tivdak is for intravenous infusion only and should not be given as an intravenous push or bolus. Avoid mixing or infusing it with other medications.